Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam to Sell $86.9M in Stock

Premium

Alnylam Pharmaceuticals this week announced that it would offer for sale 8.625 million of its shares at $10.75 per share.

The company's shares have been trading around $12.50 this week.

Alnylam is offering 7.5 million shares to the public, and the underwriters of the offering have exercised an option to purchase 1.125 million additional shares.

The transaction, which would pull in $86.9 million for the company, is expected to close on Feb. 21.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.